Patent intelligence · US
US 12144815
Use of aprepitant for treating Alzheimer's disease
Use of aprepitant for treating Alzheimer's disease
Patent details — US 12144815
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 19, 2024
- Expiration
- Nov 14, 2044
- Applicant
- Hoth Therapeutics, Inc.
- Claims
- 27
- CPC classes
- A61K, A61K31/192, A61K31/27, A61K31/407
Quick answer
US 12144815 (Use of aprepitant for treating Alzheimer's disease) is held by Hoth Therapeutics, Inc.. Status: granted. Granted Nov 19, 2024. Expires Nov 14, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Hoth Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 27
- CPC classes
- A61K, A61K31/192, A61K31/27, A61K31/407, A61K31/415, A61K31/4425
Frequently asked questions
What is US patent 12144815?
US 12144815 (Use of aprepitant for treating Alzheimer's disease) is held by Hoth Therapeutics, Inc.. Status: granted. Granted Nov 19, 2024. Expires Nov 14, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12144815?
Hoth Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 12144815 expire?
Our index shows an expiration date of Nov 14, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.